A global clinical investigation, spearheaded by a consortium of international academic institutions including McMaster University, has illuminated a promising therapeutic avenue for individuals grappling with the debilitating fatigue characteristic of long COVID. The study, a randomized, placebo-controlled trial published in the esteemed Annals of Internal Medicine, demonstrated that fluvoxamine, a widely recognized antidepressant, can significantly mitigate fatigue and enhance the overall quality of life for adults afflicted with this prolonged post-viral syndrome. This inexpensive medication, already established in the pharmacopoeia for treating conditions such as obsessive-compulsive disorder and depression, now presents itself as a potential cornerstone in managing one of long COVID’s most prevalent and incapacitating symptoms.
The pervasive nature of fatigue following SARS-CoV-2 infection cannot be overstated; for a substantial segment of the affected population, this exhaustion transcends mere tiredness, encroaching upon their capacity to engage in employment, fulfill family obligations, and navigate the complexities of daily existence. The scarcity of evidence-based interventions for this particular symptom has left many patients in a state of considerable distress, actively seeking validated treatment options. "This represents a pivotal advancement for patients who have been yearning for evidence-based solutions," remarked Edward Mills, a senior author on the study, a distinguished professor within McMaster’s Department of Health Research Methods, Evidence, and Impact, and a co-principal investigator of the trial. He further elaborated, "Fluvoxamine exhibited consistent and clinically meaningful improvements. Given its widespread availability and established safety profile, its potential for immediate clinical application is exceptionally high."
The collaborative effort behind this groundbreaking research involved investigators from leading universities in Canada, the United States, and numerous institutions across Brazil. The clinical trial operations were primarily concentrated in Belo Horizonte and various locations within the state of Minas Gerais, Brazil, underscoring the international scope and collaborative spirit of the investigation. The REVIVE-TOGETHER trial, as it was formally known, brought together a formidable team of researchers from institutions including McMaster University, the University of British Columbia, Stanford University, the University of Pittsburgh, Duke University, Georgetown University, and a cadre of Brazilian academic and research centers.
The experimental design of the REVIVE-TOGETHER trial involved the careful recruitment of 399 adult participants residing in Brazil, all of whom had experienced persistent fatigue for a minimum of 90 days subsequent to a confirmed SARS-CoV-2 infection. These individuals were randomly assigned to one of three distinct treatment arms. One group received fluvoxamine (marketed globally under the brand name Luvox), another received metformin, a well-established medication primarily used for managing type 2 diabetes, and a third group was administered a placebo. The therapeutic intervention period for all participants lasted for 60 days. Professor Mills explained the rationale behind selecting these specific agents: "Our objective was to ascertain whether two readily accessible and economically viable medications could offer relief. Both drugs possessed plausible biological mechanisms that suggested potential efficacy against long COVID fatigue, yet neither had undergone rigorous evaluation for this specific indication in a properly controlled clinical trial."
The findings pertaining to fluvoxamine were particularly encouraging. Participants who were administered the antidepressant demonstrated a statistically significant reduction in fatigue compared to those who received the placebo. The statistical analysis yielded a remarkable 99 percent probability that fluvoxamine was superior to the placebo in alleviating fatigue. Beyond the reduction in fatigue, individuals treated with fluvoxamine also reported notable improvements in their overall quality of life, as assessed through multiple standardized measures.
In contrast, metformin did not yield comparable positive outcomes in this particular trial. While prior research had suggested that metformin, when administered during the acute phase of a COVID-19 infection, might reduce the subsequent risk of developing long COVID, its efficacy in treating established long COVID fatigue was not observed in this study. The drug provided no discernible or meaningful benefit for participants who were already suffering from chronic fatigue.
A key element contributing to the trial’s efficiency and rapid conclusion was its utilization of a sophisticated Bayesian adaptive clinical trial design. This innovative methodology allowed researchers to terminate individual treatment arms prematurely once sufficient evidence of efficacy or futility had been gathered. This adaptive approach not only accelerates the process of reaching definitive conclusions but also does so while maintaining the highest standards of scientific rigor, proving to be a methodological advancement as significant as the therapeutic findings themselves. Gilmar Reis, the lead author of the study and a researcher at Cardresearch, a Brazilian clinical research center based in Belo Horizonte, also holding a part-time associate professorship at McMaster, highlighted the design’s importance: "The trial’s advanced adaptive design enabled it to arrive at conclusions more expeditiously than conventional trial structures, allowing for early termination when the data reached a clear threshold – a design innovation that is as impactful as the results themselves."
Despite these encouraging findings, it is crucial to acknowledge that long COVID remains a complex and multifaceted global health challenge, estimated to affect approximately 65 million individuals worldwide. The current landscape of proven therapies for the condition is still limited, leading many medical professionals to rely primarily on supportive strategies. These often include guidance on pacing activities to manage energy levels and the symptomatic management of individual complaints.
The researchers involved in the study are keen to emphasize that fluvoxamine should not be considered a panacea for long COVID. The syndrome is characterized by a diverse array of symptoms and underlying biological processes, and the medication appears to be specifically beneficial for fatigue management rather than addressing the entirety of the long COVID experience. Further research is deemed essential to precisely identify which patient subgroups are most likely to benefit from fluvoxamine, to elucidate the precise mechanisms by which the drug exerts its effects on post-viral fatigue, and to explore its potential synergistic use in conjunction with other emerging therapeutic agents for long COVID. Jamie Forrest, the corresponding author and a postdoctoral research fellow at the University of British Columbia, articulated the significance of these findings: "This trial furnishes clinicians with the inaugural strong evidence supporting a medication that effectively reduces long COVID fatigue. Patients are actively seeking tangible interventions they can utilize today, and this discovery brings us considerably closer to realizing that objective." The research initiative was generously supported by funding from The Latona Foundation.
About the Author
